Ibañez Vea, María

Loading...
Profile Picture

Email Address

Birth Date

Job Title

Last Name

Ibañez Vea

First Name

María

person.page.departamento

Agronomía, Biotecnología y Alimentación

person.page.instituteName

IMAB. Research Institute for Multidisciplinary Applied Biology

person.page.observainves

person.page.upna

Name

Search Results

Now showing 1 - 2 of 2
  • PublicationOpen Access
    PD1 signal transduction pathways in T cells
    (Impact Journals, 2017) Arasanz Esteban, Hugo; Gato Cañas, María; Zuazo Ibarra, Miren; Ibañez Vea, María; Breckpot, Karine; Kochan, Grazyna; Escors Murugarren, David; Ciencias de la Salud; Osasun Zientziak; Gobierno de Navarra / Nafarroako Gobernua
    The use of immune checkpoint inhibitors for the treatment of cancer is revolutionizing oncology. Amongst these therapeutic agents, antibodies that block PD-L1/PD1 interactions between cancer cells and T cells are demonstrating high efficacies and low toxicities. Despite all the recent advances, very little is yet known on the molecular intracellular signaling pathways regulated by either PD-L1 or PD1. Here we review the current knowledge on PD1-dependent intracellular signaling pathways, and the consequences of disrupting PD1 signal transduction.
  • PublicationOpen Access
    PDL1 signals through conserved sequence motifs to overcome interferon-mediated cytotoxicity
    (Elsevier, 2017) Gato Cañas, María; Zuazo Ibarra, Miren; Arasanz Esteban, Hugo; Ibañez Vea, María; Lorenzo, Laura; Fernández Hinojal, Gonzalo; Vera García, Ruth; Smerdou, Cristian; Martisova, Eva; Arozarena Martinicorena, Imanol; Wellbrock, Claudia; Llopiz, Diana; Ruiz, Marta; Sarobe, Pablo; Breckpot, Karine; Kochan, Grazyna; Escors Murugarren, David; Ciencias de la Salud; Osasun Zientziak; Universidad Pública de Navarra / Nafarroako Unibertsitate Publikoa; Gobierno de Navarra / Nafarroako Gobernua
    PDL1 blockade produces remarkable clinical responses, thought to occur by T cell reactivation through prevention of PDL1-PD1 T cell inhibitory interactions. Here, we find that PDL1 cell-intrinsic signaling protects cancer cells from interferon (IFN) cytotoxicity and accelerates tumor progression. PDL1 inhibited IFN signal transduction through a conserved class of sequence motifs that mediate crosstalk with IFN signaling. Abrogation of PDL1 expression or antibody-mediated PDL1 blockade strongly sensitized cancer cells to IFN cytotoxicity through a STAT3/caspase-7-dependent pathway. Moreover, somatic mutations found in human carcinomas within these PDL1 sequence motifs disrupted motif regulation, resulting in PDL1 molecules with enhanced protective activities from type I and type II IFN cytotoxicity. Overall, our results reveal a mode of action of PDL1 in cancer cells as a first line of defense against IFN cytotoxicity.